Heron Therapeutics Stock News

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO , March 10, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class tre

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formula

Short interest is high on these penny stocks. Time to buy or avoid them entirely? The post Best Penny Stocks This Week? 4 Short Squeeze Stocks To Watch appeared first on Penny Stocks to Buy, Picks, Ne

Short interest is high on these penny stocks. Time to buy or avoid them entirely?

Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54. SoundHound AI, Inc. (NASDAQ: SOUN) shares climbed 39.7% to $3.9394. Shar

Short squeeze penny stocks to buy now or avoid entirely? The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | P

Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | Penny

Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?

Some good news is finally starting to creep into the markets with inflation easing in October. However, GDP growth remains a concern.

Heron Therapeutics Inc (NASDAQ: HRTX) reported a Q3 EPS loss of $(0.38), in line with consensus, with sales of $26.60 million missing the consensus of $26.96 million. Needham notes it was another u

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - CEO and Chairman John Poyhonen - Pr